RESEARCH USE ONLY: All products are for laboratory research purposes only. Not for human or animal consumption.
By using this site, you confirm you are 21+ and acknowledge these products are not FDA approved.
← Back to Research Library
Mechanism of Action
Semaglutide is a long-acting GLP-1 receptor agonist with 94% homology to native GLP-1. A C-18 fatty diacid enables albumin binding and ~7-day half-life. It enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and activates hypothalamic appetite-suppression circuits.
Key Research Findings
- STEP 1: 14.9% mean weight loss at 68 weeks vs 2.4% with placebo in 1,961 adults
- SELECT: 20% reduction in MACE in overweight/obese patients without diabetes
- SUSTAIN-6: 26% reduction in cardiovascular events in T2DM patients
- FLOW: 24% kidney disease progression risk reduction in T2DM-CKD patients
Peer-Reviewed Studies (4)
Wilding JPH, Batterham RL, et al.
New England Journal of Medicine (2021)
Semaglutide 2.4mg produced 14.9% body weight reduction vs 2.4% placebo at 68 weeks (STEP 1)
Lincoff AM, Brown-Frandsen K, et al.
New England Journal of Medicine (2023)
20% reduction in MACE with semaglutide in overweight/obese adults (SELECT trial)
Marso SP, Bain SC, et al.
New England Journal of Medicine (2016)
26% reduction in cardiovascular events with semaglutide vs placebo (SUSTAIN-6)
Perkovic V, Tuttle KR, et al.
New England Journal of Medicine (2024)
24% kidney disease progression risk reduction (FLOW trial)
Research Disclaimer: The studies referenced above are from publicly available peer-reviewed literature. Pepta Labs products are sold strictly for research purposes. They are not intended for human consumption, therapeutic use, or as dietary supplements. All information is provided for educational and research reference only.